Literature DB >> 24744142

7B7: a novel antibody directed against the Ku70/Ku80 heterodimer blocks invasion in pancreatic and lung cancer cells.

Dermot O'Sullivan1, Michael Henry, Helena Joyce, Naomi Walsh, Edel Mc Auley, Paul Dowling, Niall Swan, Michael Moriarty, Paul Barnham, Martin Clynes, Annemarie Larkin.   

Abstract

Development of more effective therapeutic strategies for cancers of high unmet need requires the continued discovery of disease-specific protein targets for therapeutic antibody targeting. In order to identify novel proteins associated with cancer cell invasion/metastasis, we present here an alternative to antibody targeting of cell surface proteins with an established role in invasion; our functional antibody screening approach involves the isolation and selection of MAbs that are primarily screened for their ability to inhibit tumour invasion. A clonal population of the Mia PaCa-2, a pancreatic ductal adenocarcinoma (PDAC) cell line, which displays a highly invasive phenotype, was used to generate MAbs with the objective of identifying membrane targets directly involved in cancer invasion. Selected MAb 7B7 can significantly reduce invasion in a dose-responsive manner in Mia PaCa-2 clone 3 and DLKP-M squamous lung carcinoma cells. Using immunoprecipitation and liquid chromatography-tandem mass spectrometry (LC-MS-MS) analysis, the target antigen of anti-invasive antibody, 7B7, was determined to be the heterodimeric Ku antigen, Ku70/80, a core protein composed of the Ku70 and Ku80 subunits which is involved in non-homologous end-joining (NHEJ) DNA repair. RNA interference-mediated knockdown of Ku70 and Ku80 resulted in a marked decrease in the invasive capacity of Mia PaCa-2 clone 3 and DLKP-M cells, indicating that Ku70/Ku80 is functionally involved in pancreatic and lung cancer invasion. Immunohistochemical analysis demonstrated Ku70/Ku80 immunoreactivity in 37 PDAC tumours, indicating that this heterodimer is highly expressed in this aggressive cancer type. This study demonstrates that a functional MAb screening approach coupled with immunoprecipitation/proteomic analyses can be successfully applied to identify functional anti-invasive MAbs and potential novel targets for therapeutic antibody targeting.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24744142     DOI: 10.1007/s13277-014-1857-5

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  43 in total

Review 1.  Strategies and challenges for the next generation of therapeutic antibodies.

Authors:  Alain Beck; Thierry Wurch; Christian Bailly; Nathalie Corvaia
Journal:  Nat Rev Immunol       Date:  2010-05       Impact factor: 53.106

2.  In-gel digestion for mass spectrometric characterization of proteins and proteomes.

Authors:  Andrej Shevchenko; Henrik Tomas; Jan Havlis; Jesper V Olsen; Matthias Mann
Journal:  Nat Protoc       Date:  2006       Impact factor: 13.491

3.  Aldehyde dehydrogenase 1A1 and gelsolin identified as novel invasion-modulating factors in conditioned medium of pancreatic cancer cells.

Authors:  Naomi Walsh; Paul Dowling; Norma O'Donovan; Michael Henry; Paula Meleady; Martin Clynes
Journal:  J Proteomics       Date:  2008-09-25       Impact factor: 4.044

4.  Maturing antibody-drug conjugate pipeline hits 30.

Authors:  Asher Mullard
Journal:  Nat Rev Drug Discov       Date:  2013-05       Impact factor: 84.694

5.  The nuclear DNA repair protein Ku70/80 is a tumor-associated antigen displaying rapid receptor mediated endocytosis.

Authors:  Johan Fransson; Carl A K Borrebaeck
Journal:  Int J Cancer       Date:  2006-11-15       Impact factor: 7.396

6.  Malignant T cells in cutaneous T-cell lymphoma lesions contain decreased levels of the antiapoptotic protein Ku70.

Authors:  K Ferenczi; J Ohtola; P Aubert; M Kessler; H Sugiyama; A K Somani; A C Gilliam; J Z Chen; I Yeh; S Matsuyama; T S McCormick; K D Cooper
Journal:  Br J Dermatol       Date:  2010-09       Impact factor: 9.302

Review 7.  Strategies for the discovery and development of therapies for metastatic breast cancer.

Authors:  Bedrich L Eckhardt; Prudence A Francis; Belinda S Parker; Robin L Anderson
Journal:  Nat Rev Drug Discov       Date:  2012-06-01       Impact factor: 84.694

8.  Abnormal DNA-PKcs and Ku 70/80 expression may promote malignant pathological processes in gastric carcinoma.

Authors:  Wei Li; Chuan Xie; Zhen Yang; Jiang Chen; Nong-Hua Lu
Journal:  World J Gastroenterol       Date:  2013-10-28       Impact factor: 5.742

9.  Function-first antibody discovery: Embracing the unpredictable biology of antibodies.

Authors:  Björn Frendéus
Journal:  Oncoimmunology       Date:  2013-05-20       Impact factor: 8.110

10.  Radiosensitisation of bladder cancer cells by panobinostat is modulated by Ku80 expression.

Authors:  Blaz Groselj; Martin Kerr; Anne E Kiltie
Journal:  Radiother Oncol       Date:  2013-08-06       Impact factor: 6.280

View more
  3 in total

1.  XRCC5 cooperates with p300 to promote cyclooxygenase-2 expression and tumor growth in colon cancers.

Authors:  Zhifeng Zhang; Fufu Zheng; Zhenlong Yu; Jiajiao Hao; Miao Chen; Wendan Yu; Wei Guo; Yiming Chen; Wenlin Huang; Zhijun Duan; Wuguo Deng
Journal:  PLoS One       Date:  2017-10-19       Impact factor: 3.240

2.  Hsa-miR-623 suppresses tumor progression in human lung adenocarcinoma.

Authors:  Shuang Wei; Zun-Yi Zhang; Sheng-Ling Fu; Jun-Gang Xie; Xian-Sheng Liu; Yong-Jian Xu; Jian-Ping Zhao; Wei-Ning Xiong
Journal:  Cell Death Dis       Date:  2016-09-29       Impact factor: 8.469

3.  A novel inhibitory anti-invasive MAb isolated using phenotypic screening highlights AnxA6 as a functionally relevant target protein in pancreatic cancer.

Authors:  Dermot O'Sullivan; Paul Dowling; Helena Joyce; Edel McAuley; Andrew McCann; Michael Henry; Brianan McGovern; Paul Barham; Fergal C Kelleher; Jean Murphy; Susan Kennedy; Niall Swan; Michael Moriarty; Martin Clynes; Annemarie Larkin
Journal:  Br J Cancer       Date:  2017-09-07       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.